This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Alkermes Initiates Clinical Study Of ALKS 5461 For Treatment-Resistant Depression

Stocks in this article: ALKS

Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy. The multicenter, randomized, double-blind, placebo-controlled trial is designed to assess the safety and potential efficacy of ALKS 5461 in subjects with TRD. Alkermes expects to provide topline results from this study in the second half of calendar 2011.

"Many patients with depression do not adequately respond to existing pharmacological therapies, underscoring the unmet need for this serious and chronic disease," stated Elliot Ehrich, Chief Medical Officer of Alkermes. "The combination of ALKS 33 with buprenorphine to create ALKS 5461 leverages our expertise with opioid modulators and may create a non-addictive therapy for treatment-resistant depression."

The phase 1/2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, multi-dose study is designed to evaluate the safety and tolerability of ALKS 5461 in 32 patients with major depressive disorder who had shown an inadequate response to previous antidepressant therapy. Two different ratios of the components will be given in an escalating dose titration once daily for seven days via sublingual administration. The pharmacokinetics and efficacy of ALKS 5461 will also be evaluated.

ALKS 5461 is designed to be a non-addictive, kappa antagonist for the treatment of TRD. Preclinical research has demonstrated that kappa blockade has antidepressant effects in behavioral models of depression. Both components of ALKS 5461 have established activity at mu opioid receptors, with ALKS 33 functioning as an antagonist of the mu receptor and buprenorphine as a partial agonist. The net effect of this combination may attenuate buprenorphine’s mu agonist effects, therefore making it potentially non-addictive.

About ALKS 5461

ALKS 5461 is the combination of ALKS 33 and buprenorphine. ALKS 33 is an oral opioid modulator that builds on Alkermes' scientific expertise in opioid biology and pharmacology, as well as the company’s clinical and commercial knowledge in the field of addiction and central nervous system disorders. Clinical studies of ALKS 33 in over 400 patients to date have shown that it is generally well tolerated with a duration of action consistent with once-daily dosing. ALKS 5461 is also in clinical development for the treatment of cocaine addiction, which is being funded through a grant from the National Institute on Drug Abuse (NIDA).

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs